



AstraZeneca Pharma India Limited

Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

FINANCIAL RESULTS FOR THE QUARTER AND FIFTEEN MONTHS ENDED 31 MARCH 2011

Rs in lakhs (except for number of shares)

Sl No.	Particulars	3 months ended	3 months ended	Year to date	Previous
		31.03.2011	31.03.2010	figures for current period ended 31.03.2011	accounting year ended 31.12.2009
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	(a) Net sales (net of excise duty)	12,330.47	9,228.41	57,436.20	38,552.12
	(b) Other operating income: "Service income"	337.21	562.38	1,966.30	1,111.21
2	Expenditure	(99.78)	(401.06)	(1,358.95)	12.76
	(a) (increase) / decrease in stock-in-trade and work-in-progress	1,640.44	1,329.86	7,604.40	4,575.41
	(b) Consumption of raw materials and packing materials	2,418.86	2,022.81	11,691.17	7,507.77
	(c) Purchase of traded goods	3,829.81	2,680.50	15,049.76	8,282.94
	(d) Employment cost	175.63	157.61	881.28	607.67
	(e) Depreciation	3,218.77	3,657.50	16,074.49	10,388.26
	(f) Other expenditure	11,183.55	9,447.34	49,932.15	31,384.81
	Total	1,484.13	343.45	9,470.35	8,276.52
3	Profit from operations before other income, interest & exceptional items (1-2)	218.79	58.64	628.14	574.40
4	Other income	1,703.92	402.09	10,098.49	8,852.92
5	Profit before interest & exceptional items (3+4)	-	-	-	13.70
6	Interest	1,703.92	402.09	10,098.49	8,839.22
7	Profit after interest but before exceptional items (5-6)	-	-	-	-
8	Exceptional items	1,703.92	402.09	10,098.49	8,839.22
9	Profit from ordinary activities before tax (7+8)	868.53	140.69	3,685.52	3,077.49
10	Tax expense	835.39	261.40	6,412.97	5,761.73
11	Net profit from ordinary activities after tax (9-10)	33.14	(120.71)	(272.45)	(2682.24)
12	Extraordinary item	835.39	261.40	6,412.97	5,761.73
13	Net profit for the period (11-12)	500.00	500.00	500.00	500.00
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	-	-	-	-
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year	3.34	1.05	17,468.36	13,951.82
16	Basic and diluted earnings (Rs) per share (not annualised)	0.0002%	0.0002%	0.0002%	0.0002%
17	Public shareholding	2,500,050	2,500,050	2,500,050	2,500,050
	- Number of shares	10.0002%	10.0002%	10.0002%	10.0002%
	- Percentage of shareholding	-	-	-	-
18	Promoters and promoter group shareholding	22,489,950	22,489,950	22,489,950	22,489,950
	a) Pledged/Encumbered	-	-	-	-
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
	b) Non-encumbered	100%	100%	100%	100%
	- Number of shares	89.9998%	89.9998%	89.9998%	89.9998%
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-

Notes:

- The above statement of financial results were reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 13 May 2011.
- Status of investor complaints: a) Pending as on 1 January 2011 - Nil. b) Received during the quarter - 6 c) Disposed off during the quarter - 6 d) Pending as on 31 March 2011 - Nil.
- The Board of Directors at their meeting held on 23 February 2010 approved the change in the Company's statutory accounting year from "January-December" to "April-March". Accordingly, the financial accounts and annual report for the year ending 31 March 2011 are for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Which comprises service income pertaining to clinical trials and co-promotion activities.
- The Board of Directors at their meeting held on 13 May 2011 have recommended Rs.10 (previous year Rs. 10) as dividend per equity share of Rs 2 each for the period ended 31 March 2011.
- Previous period figures have been regrouped / reclassified, wherever necessary to conform to the current period's presentation.

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Sl No.	Particulars	3 months ended	Corresponding	15 months	Previous
		31.03.2011	3 months ended in the previous year 31.03.2010	ended 31.03.2011	Accounting year ended 31.12.2009
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Segment Revenue	12,336.22	9,233.64	57,464.43	38,583.37
	(a) Healthcare	337.21	562.38	1,966.30	1,129.28
	(b) Others	12,673.43	9,796.02	59,438.73	39,712.65
	Total	12,673.43	9,796.02	59,438.73	39,712.65
	Less: Inter-segment Revenue	-	-	-	-
	Net Income From Operations	12,673.43	9,796.02	59,438.73	39,712.65
2	Segment Results	1,539.44	305.70	9,386.50	8,206.13
	Profit before Tax and interest	(49.50)	42.98	112.08	23.85
	(a) Healthcare	1,489.88	348.68	9,498.58	8,309.78
	(b) Others	214.04	53.41	599.91	543.14
	Add: Other Income	-	-	-	13.70
	Less: Interest	1,703.92	402.09	10,098.49	8,839.22
	Total Profit Before Tax	1,703.92	402.09	10,098.49	8,839.22
3	Capital Employed	12,122.33	9,348.46	12,122.33	11,595.38
	(a) Healthcare	644.20	(21.71)	644.20	(378.11)
	(b) Others	5,202.43	5,386.47	5,202.43	3,234.55
	(c) Unallocated	17,968.96	14,713.22	17,968.96	14,451.82
	Total	17,968.96	14,713.22	17,968.96	14,451.82

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

By Order of the Board of Directors
For ASTRAZENECA PHARMA INDIA LIMITED

Anandh Balasundaram
Managing Director

Place : Bangalore
Dated : 13 May 2011